Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

Robert Orlowski; Thierry Facon; Shaji Kumar; Torben Plesner; Philippe Moreau; Nizar Bahlis; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut Goldschmidt; Michael O'Dwyer; Aurore Perrot; Christopher Venner; Katja Weisel; Joseph Mace; Noopur Raje; Mourad Tiab; Margaret Macro; Laurent Frenzel; Xavier Leleu; Tahamtan Ahmadi; Jianping Wang; Rian Van Rampelbergh; Clarissa Uhlar; Brenda Tromp; Maria Delioukina; Jessica Vermeulen; Saad Usmani

doi:10.1016/S2152-2650(21)01950-9

Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

Robert Orlowski, Thierry Facon, Shaji Kumar, Torben Plesner, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher Venner, Katja Weisel, Joseph Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent FrenzelXavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Usmani

IRS - Lillebælt Hospital, Research Unit of Haematology (Vejle)

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Journal	Clinical Lymphoma Myeloma and Leukemia
Volume	21
Issue number	Suppl. 1
Pages (from-to)	S424-S425
ISSN	2152-2650
DOIs	https://doi.org/10.1016/S2152-2650(21)01950-9
Publication status	Published - 1. Sept 2021
Event	The ninth annual meeting of the Society of Hematologic Oncology - Virtuelt Duration: 8. Sept 2021 → 11. Sept 2021 Conference number: 9

Conference

Conference	The ninth annual meeting of the Society of Hematologic Oncology
Number	9
Location	Virtuelt
Period	08/09/2021 → 11/09/2021

Keywords

MM
transplant-ineligible
newly diagnosed multiple myeloma
daratumumab

Documents & Links

10.1016/S2152-2650(21)01950-9

Cite this

Orlowski, R., Facon, T., Kumar, S., Plesner, T., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C., Weisel, K., Mace, J., Raje, N., Tiab, M., Macro, M., ... Usmani, S. (2021). Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). Clinical Lymphoma Myeloma and Leukemia, 21(Suppl. 1), S424-S425. https://doi.org/10.1016/S2152-2650(21)01950-9

Orlowski, Robert ; Facon, Thierry ; Kumar, Shaji et al. / Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). In: Clinical Lymphoma Myeloma and Leukemia. 2021 ; Vol. 21, No. Suppl. 1. pp. S424-S425.

@article{425863865dcd4925ad57f24a6f6c172a,

title = "Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)",

keywords = "MM, transplant-ineligible, newly diagnosed multiple myeloma, daratumumab",

author = "Robert Orlowski and Thierry Facon and Shaji Kumar and Torben Plesner and Philippe Moreau and Nizar Bahlis and Supratik Basu and Hareth Nahi and Cyrille Hulin and Hang Quach and Hartmut Goldschmidt and Michael O'Dwyer and Aurore Perrot and Christopher Venner and Katja Weisel and Joseph Mace and Noopur Raje and Mourad Tiab and Margaret Macro and Laurent Frenzel and Xavier Leleu and Tahamtan Ahmadi and Jianping Wang and {Van Rampelbergh}, Rian and Clarissa Uhlar and Brenda Tromp and Maria Delioukina and Jessica Vermeulen and Saad Usmani",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/S2152-2650(21)01950-9",

language = "English",

volume = "21",

pages = "S424--S425",

journal = "Clinical Lymphoma Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "Suppl. 1",

note = "The ninth annual meeting of the Society of Hematologic Oncology ; Conference date: 08-09-2021 Through 11-09-2021",

}

Orlowski, R, Facon, T, Kumar, S, Plesner, T, Moreau, P, Bahlis, N, Basu, S, Nahi, H, Hulin, C, Quach, H, Goldschmidt, H, O'Dwyer, M, Perrot, A, Venner, C, Weisel, K, Mace, J, Raje, N, Tiab, M, Macro, M, Frenzel, L, Leleu, X, Ahmadi, T, Wang, J, Van Rampelbergh, R, Uhlar, C, Tromp, B, Delioukina, M, Vermeulen, J & Usmani, S 2021, 'Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)', Clinical Lymphoma Myeloma and Leukemia, vol. 21, no. Suppl. 1, pp. S424-S425. https://doi.org/10.1016/S2152-2650(21)01950-9

Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). / Orlowski, Robert; Facon, Thierry; Kumar, Shaji et al.
In: Clinical Lymphoma Myeloma and Leukemia, Vol. 21, No. Suppl. 1, 01.09.2021, p. S424-S425.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

AU - Orlowski, Robert

AU - Facon, Thierry

AU - Kumar, Shaji

AU - Plesner, Torben

AU - Moreau, Philippe

AU - Bahlis, Nizar

AU - Basu, Supratik

AU - Nahi, Hareth

AU - Hulin, Cyrille

AU - Quach, Hang

AU - Goldschmidt, Hartmut

AU - O'Dwyer, Michael

AU - Perrot, Aurore

AU - Venner, Christopher

AU - Weisel, Katja

AU - Mace, Joseph

AU - Raje, Noopur

AU - Tiab, Mourad

AU - Macro, Margaret

AU - Frenzel, Laurent

AU - Leleu, Xavier

AU - Ahmadi, Tahamtan

AU - Wang, Jianping

AU - Van Rampelbergh, Rian

AU - Uhlar, Clarissa

AU - Tromp, Brenda

AU - Delioukina, Maria

AU - Vermeulen, Jessica

AU - Usmani, Saad

N1 - Conference code: 9

PY - 2021/9/1

Y1 - 2021/9/1

KW - MM

KW - transplant-ineligible

KW - newly diagnosed multiple myeloma

KW - daratumumab

U2 - 10.1016/S2152-2650(21)01950-9

DO - 10.1016/S2152-2650(21)01950-9

M3 - Conference abstract in journal

SN - 2152-2650

VL - 21

SP - S424-S425

JO - Clinical Lymphoma Myeloma and Leukemia

JF - Clinical Lymphoma Myeloma and Leukemia

IS - Suppl. 1

T2 - The ninth annual meeting of the Society of Hematologic Oncology

Y2 - 8 September 2021 through 11 September 2021

ER -

Orlowski R, Facon T, Kumar S, Plesner T, Moreau P, Bahlis N et al. Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). Clinical Lymphoma Myeloma and Leukemia. 2021 Sept 1;21(Suppl. 1):S424-S425. doi: 10.1016/S2152-2650(21)01950-9